HDBNJ-3049

N/A

Report date: 2025/07/08 16:57:10
NME

Base Information

Drug NameHDBNJ-3049
Drug Alias NameHDBNJ-3049
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 degraders
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBNJ Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesBNJ Biopharma
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A